Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
Deal Structure and Financial Terms
The acquisition is valued at USD 2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments of up to approximately USD 1.125 billion. The transaction is expected to close before the end of 2026, subject to applicable regulatory approvals and customary closing conditions.
Alongside the acquisition, Johnson & Johnson will enter into a separate development funding agreement with Blackstone Life Sciences to support the Phase 3 clinical advancement of OLN324, contingent upon the acquisition's close.
Under that arrangement, Blackstone will pay a total of USD 750 million to Johnson & Johnson over multiple years to fully fund the Phase 3 development of OLN324.
In return, Blackstone will be eligible to receive certain regulatory and sales milestone payments as well as single-digit royalties. The accounting treatment will be communicated on or before the transaction closes.
What OLN324 Brings to the Pipeline
The acquisition would add OLN324 to Johnson & Johnson's pipeline. OLN324 is an investigational bispecific antibody designed to target two key pathways in retinal diseases: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2).
The molecule is described as a next-generation antibody with high Ang2 potency and a small protein format, referred to as a minibody, that could enable improved control of retinal fluid.
OLN324 is being developed for retinal vascular diseases, including wet age-related macular degeneration (AMD) and diabetic macular edema. According to the announcement, those conditions together affect well over 40 million people worldwide and are leading causes of vision loss. OLN324 is currently in Phase 3 development.
Trusted by Leading EPCs & Manufacturers
Find the Latest Pharmaceutical Plant Projects in the United States
Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information
Request Free Trial → Learn More →
No credit card Up-to-date coverage
Company Commentary
Kip Connor, Vice President and Ophthalmology Disease Area Stronghold Leader at Johnson & Johnson, said the compound selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control.
He stated that the data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.
The company stated that its combination of scientific, development, and commercial capabilities positions it to advance OLN324 and build on Ollin's promising science.
Johnson & Johnson framed the proposed acquisition as strengthening its leadership in ophthalmology and its commitment to preserve, restore, and enhance vision for millions of people worldwide.
The deal is also described as accelerating the company's ambition to preserve, restore, and enhance vision and as building on Johnson & Johnson's long-standing presence as an innovator in vision.
Your Gateway to Every Major Development in the US Chemical Sector
Keeping track of capital projects in the United States chemical sector doesn't have to involve sifting through news articles, government websites, and outdated databases. Imagine if every project milestone, from announcement to completion, was consolidated in one location, available whenever you need it.
The Global Project Tracking (GPT) platform by Blackridge Research consolidates real-time intelligence on chemical sector developments, enabling your team to seize opportunities ahead of competitors.
With coverage spanning the US chemical project lifecycle, you get a complete picture of market activity at every stage; not just snapshots of what's already been decided.
Upcoming Projects
Tender Notices
Contract Awards
Projects Under Construction
Completed Projects
Book a Free Demo today and see how the Global Project Tracking (GPT) platform by Blackridge Research can power your chemical sector growth strategy in the United States.
Leave a Comment
We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.
We read every comment and do our best to respond to them all.